Does ORITAVANCIN DIPHOSPHATE Cause Off label use? 49 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 49 reports of Off label use have been filed in association with ORITAVANCIN DIPHOSPHATE (Kimyrsa). This represents 17.8% of all adverse event reports for ORITAVANCIN DIPHOSPHATE.
49
Reports of Off label use with ORITAVANCIN DIPHOSPHATE
17.8%
of all ORITAVANCIN DIPHOSPHATE reports
0
Deaths
8
Hospitalizations
How Dangerous Is Off label use From ORITAVANCIN DIPHOSPHATE?
Of the 49 reports, 8 (16.3%) required hospitalization, and 2 (4.1%) were considered life-threatening.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ORITAVANCIN DIPHOSPHATE. However, 49 reports have been filed with the FAERS database.
What Other Side Effects Does ORITAVANCIN DIPHOSPHATE Cause?
Multiple use of single-use product (102)
Chills (87)
Infusion related reaction (63)
Back pain (41)
Pruritus (36)
Dyspnoea (35)
Flushing (35)
Tremor (35)
Nausea (33)
Rash (25)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which ORITAVANCIN DIPHOSPHATE Alternatives Have Lower Off label use Risk?
ORITAVANCIN DIPHOSPHATE vs ORLISTAT
ORITAVANCIN DIPHOSPHATE vs ORNIDAZOLE
ORITAVANCIN DIPHOSPHATE vs ORPHENADRINE
ORITAVANCIN DIPHOSPHATE vs OSELTAMIVIR
ORITAVANCIN DIPHOSPHATE vs OSILODROSTAT